Business
Advanced Biomed is a holding company developing microfluidic and semiconductor-based technologies for cancer detection, diagnosis, staging, and treatment support.
Advanced Biomed's equity improved after its IPO, but losses and cash burn worsened with no revenue in the local bundle.
The read at a glance✓ Audited against SEC data
- Business mix — Microfluidic cancer detection platformNote
- Revenue — No revenue in local bundleNote
- Profitability — Net loss worsened to $3.3MWatch
- Cash burn — Free cash flow was -$5.9MWatch
- Balance sheet — Equity more than doubled to $3.5MOK
- Insiders — 0 buys / 0 sellsNote
- Accounting — Going-concern warningWatch
Leadership changes
From Advanced Biomed Inc.'s own filings, the day they're filed.
- Xiaomin Chen · Chief Executive Officer · appointmenteff. 2026-04-28
- Mingze Yin · director · appointmenteff. 2026-03-25
- Steven I-Fang Cheng · Chief Technology Officer · departureeff. 2026-03-25
Latest filings
- 8-K · Company announcement2026-07-01
- 8-K · Company announcement2026-06-30
- DEF 14A · Annual proxy (pay & governance)2026-06-04
- 10-Q · Quarterly report2026-05-15
- 8-K · Company announcement2026-05-01
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Advanced Biomed Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.